Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

Contrarian investing advice from biotech and pharmaceutical stock expert Hartaj Singh, Founding Partner of Tecumseh Partners ...

Sam Altman, best known as the CEO of OpenAI, has steadily built a large and diverse investment portfolio that spans ...

Discover the key biotech trends moving the industry forward in Europe at a time when there lies uncertainty in global ...

Take a closer look at London's biotech hub – renowned for its thriving life sciences ecosystem and world-class infrastructure ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

PolyActiva is taking its high-precision glaucoma implant to global trials in a test for Australia’s biotech ambitions.

In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were up ...

The Greater Baltimore Committee’s latest investment summit captured the optimism of an ecosystem bolstered by big private employers, startups, universities, government and beyond.